Consistently, Shaw et al. reported that Spry2 functions as a tumor suppressor in the context of a germline oncogenic KRAS mutation—KRASG12D—in which loss of Spry2 increased the number and overall burden of lung tumors in mice [31]. The gene discussed is KRAS; the disease is neoplasm.